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Background: Cancer stem cells (CSCs) are believed to be ‘seed cell’ in cancer recurrence and metastasis. MicroRNAs
(miRNAs) can play an important role in the progression of primary tumor towards metastasis by regulating the
epithelial-mesenchymal transition (EMT). The goal of this study was to investigate the effect of miRNA-200c
overexpression on the EMT, tumorigenicity and metastasis of epithelial ovarian cancer (EOC) CSCs.
Methods: The EOC CD117+CD44+CSCs were isolated from the human ovarian cancer cell line SKOV3 by using a
magnetic-activated cell sorting system, and the lentivirus miR-200c transduced CSCs were then selected for the
study. The assays of colony forming, wound healing, cellular migration in vitro and tumor progression in vivo were
performed.
Results: The miR-200c expression was reduced in the CD117+CD44+CSCs compared with the non-CD117+CD44+CSCs.
However, the stable overexpression of the miR-200c in the CD117+CD44+CSCs resulted in a significant
down-regulation of ZEB-1 and the Vimentin expression, an upregulation of the E-cadherin expression as well as a
decrease of colony forming, migratory and invasion in vitro. Importantly, the miR-200c overexpression significantly
inhibited the CD117+CD44+CSCs xenograft growth and lung metastasis in vivo in nude mice by inhibition of the
EMT. In addition, the down-regulation of ZEB-1 showed the same efficacy as the miR-200c overexpression in the
CD117+CD44+CSCs.
Conclusion: These findings from this study suggest that the miR-200c overexpression may be considered a critical
approach for the EOC CD117+CD44+CSCs in clinical trials.
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MetastasisBackground
Ovarian cancer is the leading cause of mortality in gyneco-
logic malignancy. The 5-year survival rate of stage III-IV
ovarian cancer patients is about 20% [1,2]. Ovarian cancer
is currently treated with a combination of surgery and
chemotherapy. Systemic chemotherapy is initially effective* Correspondence: njdoujun@yahoo.com.cn
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reproduction in any medium, provided the orin 80% of patients, however, recurrent ovarian cancer’s re-
sponds to additional chemotherapy treatments becomes
lower after each treatment cycle, as chemoresistance in-
creases until the disease becomes incurable [3]. It is there-
fore crucial to conduct an in-depth investigation of the
biology of ovarian cancer. The major advance of tumor
biology in recent years has been the discovery of the
cancer stem cells (CSCs), which play pivotal roles in
cancer progression and treatment resistance in various
neoplastic diseases. CSCs may open up new possibilitiestd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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chemoradiation and improving therapeutic efficacy [4].
Tumor metastasis has been considered the main
cause of death in patients of various malignant tumors.
Evidence from past studies has indicated that the CSC-
like cells might be generated by processes that are re-
lated to aberrant activation of the epithelial- mesenchymal
transition (EMT) that impacts cell differentiation and
tumor metastatic potential. Therefore, an anti-EMT
strategy would be a novel therapeutic option for treating
aggressive cancers [5,6]. There is increasing evidence
that the microRNAs (miRNAs) have emerged as poten-
tial therapeutic candidates by virtue of their ability to
down-regulate multiple targets involved in tumor pro-
gression and metastasis, and in tumor therapeutic
resistance and relapse. In some studies, miR-200c was
found to be down-regulated in ovarian cancer cell lines
and in stage III ovarian tumors; the miR-200c down-
regulation correlated with poor prognoses. However,
restoration of the miR-200c served as a tumor suppres-
sor by directly targeting the zinc-finger E-box binding
homeobox 1 (ZEB1) to inhibit EMT and ovarian cancer
metastasis [7-10].
The epithelial ovarian cancer (EOC) is genetically
and epigenetically distinct from normal ovarian sur-
face epithelial cells and is involved in the EMT
during cancer initiation and progression including
cancer metastasis and recurrence. ZEB1 is known to
be associated with the EOC invasive and metastatic
progression; ZEB1 is also known to be expressed in
the EOC and be able to directly repress the epithe-
lial marker E-cadherin to induce tumor cell invasive
and metastatic progression [11-14]. However, much
less information of the EMT is available about the
miRNA in the EOC CSCs, and the exact molecular
mechanism of modulating the EMT of the EOC
CSCs is yet to be elucidated.
Our goal for this study was to assess the epigenetically
regulation function of the miR-200c overexpression in
the EMT, the tumorigenicity, and the metastasis of the
EOC CD117+CD44+CSCs in vitro and in vivo. To
accomplish this goal, we transduced the lentivirus miR-
200c vector into the CD117+CD44+CSCs that were
isolated from the human EOC SKOV3 cell line [15,16].
We found in vitro a direct association between the
miR-200c overexpression and the capability of the
CD117+CD44+CSC in colony forming, migration and
invasion. In particular, we noticed the evident relation-
ship between the miR-200c and the ZEB1 expression.
Our results suggested that the miR-200c overex-
pression, by modulating the EMT, specifically inhibited
the ZEB1 expression in the CD117+CD44+CSCs and re-
duced cell tumorigenicity and lung metastasis in our
nude mouse model.Materials and methods
Cell line
The human EOC SKOV-3 cell line was from an ovarian
cancer patient of origin, which was a well-established
ovarian cancer model system. The cell line was pur-
chased from the Cellular Institute in Shanghai, China,
and was maintained in complete media consisting of
RPMI 1640, 2 mM L-glutamine, 100 U/ml penicillin,
100 μg/ml streptomycin, and 10% fetal bovine serum.
The complete media were refreshed every 3 days to
maintain the adherent cells.
Isolation of CD44+CD117+CSCs, transduction of lentivirus
miR-200c and production of stable expression colonies
The CD44+CD117+CSCs were isolated from the SKOV3
cell line by using the magnetic- associated cell sorting
(MACS) method as described previously [16,17]. Briefly,
the CD44+subsets were isolated by using the mouse anti-
human CD44 antibody coupled to magnetic microbeads
(Miltenyi Biotec., Germany); the resulting cells were then
depleted of CD117−subsets by using the mouse antihuman
CD117 antibody coupled to magnetic microbeads (Miltenyi
Biotec., Germany). The resulting CD44+CD117+cells were
labeled ‘EOC CD44+CD117+CSCs’ [15]. These cells were
further identified by using a flow cytometer (FCM,
Beckman Coulter, USA) according to the manufacturer’s
instructions. The anti-Human/ Mouse CD44 FITC and the
anti-Human CD117 PE (eBioscience, USA) antibodies were
used for the detection of the cells [18].
To generate the miR-200c expression lentivirus vector,
we amplified an insert (full-length human miR-200c) by
PCR from SKOV3 DNA. The lentivirus miR-200c was
produced from the transient transfection of the HEK293T
cells with pHAGE-CMV- miR-200c-IZsGreen, psPAX2,
and pMD2.G plasmid DNAs plus Lipofectamine 2000
(Invitrogen, USA) according to the manufacturer's pro-
tocol. Forty-eight hours after the co-transfection, the
lentivirus-bearing supernatants were collected and passed
through a 0.45-mm filter. The CD44+CD117+CSCs were
transduced with the pHAGE-CMV- miR-200c-IzsGreen
lentivirus, and were selected by the IzsGreen expression
[7,19]. The stable expression colony was generated by
limiting the dilution assay [20].
RNA isolation and quantitative RT-PCR
Total cellular RNA was isolated from a sample by using
a Qiagen RNeasy Kit (Qiagen, CA). The sequences of
the primers are as follows: the miR-200c-RT primer
5′-CTCAAC TGGTGTGGAGCGCATTCAGTTGAGT
CCATCAT-3; the ZEB1 forward, 5′-GCACAAC CAAG
GCAGAAGA-3′; reverse, 5′-CATTTGCAGTTGAGGC
TGA-3′; the β-actin forward, 5′-GGACTTCGAGCAA
GAGATGG-3′; reverse, 5′-AGCACTGTGTTGGCGTA
CAG-3′; U6: RT Primer, 5′-GTCGTATCCAGTGCAG
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TGGAAC-3′;forward, 5′-TGCGGGTGCTCGCTTCGG
CAGC-3′; URP Universal Reverse Primer, 5′-CCGGCA
GGGTCCGAGGT-3′. The E-cadherin forward: CATT
GCC ACACATACACTCTCTTCT, reverse: CGGTTAC
CGTGATCAAAATCTC; the Vimentin forward: GGA
ACAGCATGTCCAAATCG, reverse: GCACCTGTCTC
CGGTACTCA. The qRT-PCR analysis was performed
on an ABI step one plus real-time system (Applied
Biosystems, USA) [19].
Short hairpin RNA sequence design and recombinant
construction of shRNA1 targeting to ZEB1 gene
A short hairpin RNA sequence of the human ZEB1 was
designed according to the ZEB1 DNA sequence (GenBank
NO.NM_001128128.2)by the siDESIGN design software of
Dharmacon Company. The shRNA sequences were as
follows: The ZEB1-siRNA: forward, 5′- GATCCCCAG G
AAGAGGAGGAGGATAATTCAAGAGATTATCCTCCTC
CTCTTCCTTTTTTGGA AA-3′; reverse, 5′-AGCTTTT
CCAAAAAAGGAAGAGGAGG AGGATAATCTCTTG
AATTATCCTCCTCCTCTTCCTGGG-3′; the scramble-
siRNA: forward, 5′-GATCCCCTTCT CCGAACGTGTC
ACGTTTCAAGAGAACG TGACACGT TC GGAGAAT
TTTTGGAAA −3′; reverse, 5′-AGCTTTCCAAAAATT
CTCCGAACGTG TCACGTTCTCTTGAAACGTGACA
CGTTGGAGAAGGG-3′. All the primers were synthe-
sized by Company of Gene and Technology of China in
Shanghai. A pSUPER- EGFP1 (enhancement green fluores-
cent protein 1) vector was used to construct recombinants.
The recombinant pSUPER-EGFP1- ZEB1-shRNA (shZEB1)
was developed using the method described in a according
to previous reports [1,13]. A pSUPER- EGFP1-scrambled
shRNA (scramble) was used for negative control. These
recombinants were transfected by using the Lipofectamine™
2000 reagent (Invitrogen, USA) per the manufacturer’s
protocol [9].
Colony forming assay
The colony formation capabilities of the different
CD44+CD117+CSCs were investigated. Colonies larger
than 75 μm in diameter or containing more than 50
cells were counted as 1 positive colony according to
our previous reports [20,21]. About 500 cells per well
were added into a six-well culture plate, with three
wells per sample. After12-day incubation, the cells
were washed twice with PBS and stained with the
Giemsa solution. The plate clone formation efficiency
was calculated as (number of colony /number of cells
inoculated) × 100%.
Wound-healing assay
The cells from the above-mentioned colonies were grown
to confluence and were wounded by dragging a 1-mLpipette tip across their monolayer. The cells were washed
to remove any cellular debris and were then allowed to
migrate for 0, 24, and 48 hours, respectively, in a humidi-
fied 5% CO2 incubator at 37°C. Images were taken, using
a DMI6000 inverted microscope (Leica Microsystems
GmbH, Germany), at 0, 24, and 48 hours, respectively,
after the wounding procedure [22,23].
Matrigel invasion assay
The Matrigel invasion assay was done using the BD
Biocoat Matrigel Invasion Chamber (pore size: 8 mm, 24-
well; BD Biosciences, USA) following the manufacturer's
protocol [17,24]. From five randomly selected fields, the
cells that had invaded through the membrane to the lower
surface were counted under a light microscope.
Xenograft tumor model
Thirty-six five-to six-week-old female Balb/c athymic
nu/nu mice were ordered from the Animal Center of
Yang Zhou University of China and were raised at the
Experimental Animal Center, Southeast University. All
the animal experiments were performed in compliance
with the guidelines of the Animal Research Ethics Board
of Southeast University. The 36 mice were randomly
divided into six groups of equal size (6) as follows: group
1 for CD44+CD117+CSCs with lentivirus miR-200c;
group 2 for CD44+CD117+CSCs with lentivirus mock;
group 3 for CD44+CD117+CSCs without lentivirus infec-
tion; group 4 for CD44+CD117+CSCs transfected with
the shZEB1; group 5 for CD44+CD117+CSCs transfected
with the scrambled control siRNA; group 6 for CD44
+CD117+CSCs without transfection. Each mouse was
subcutaneously (s.c.) injected in the back with 5 × 104
cells for the group it was in. Tumor formations in the
mice were monitored every three days. Evaluation was
also done of the tumor volume, tumor-free mice, and
survival rates, respectively. A mouse was sacrificed when
any of its tumors was over 1.4 cm in the largest diam-
eter. The necropsy was performed on each animal for
further analysis of the primary tumor along with possible
metastases [18,25].
Western blot analysis
Total cell lysates were prepared and analyzed by using
the Western blot method as described before [26,27].
Briefly, 1 × 106 CD44+CD117+CSCs were collected and
lyzed in a protein extraction buffer according to the
manufacturer’ s protocol. The PVDF membrane was
blocked with 4% dry milk in the Tris-buffered saline
with Tween-20 for 1 h at 20°C, and was incubated with
the rabbit antibody specific to human ZEB1 (Santa cruz
Biotechnology, CA, USA ) or with E-cadherin or with
Vimentin (Bioworld Technology, USA) for overnight at
4°C. The membrane was then incubated with the anti-
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Immunoreactive bands were detected by the Odyssey
scanning instrument (LICOR Odyssey, USA ).Immunohistochemistry
4 μm-thin formalin fixed and paraffin-embedded slides
were incubated with the rabbit antibody specific to human
E-cadherin overnight at 4°C. The samples were then la-
beled with HRP-conjugated streptavidin (Invitrogen) and
the chromogenic reaction that was developed using Liquid
DAB Substrate Pack according to the manufacturer's
instructions. E-cadherin-stained cells from random and
non-overlapping fields were counted under a magnifica-
tion of × 200 [28].Tissue histopathology
The lung tissues were removed from the mice and fixed in
10% formalin, and then embedded in paraffin. Tissue sec-
tions of 4 μm thin were cut and mounted on SuperFrostFigure 1 Identification, selection and detection of the miR-200c expre
from the human EOC SKOV3 cell line were identified by FCM; B. The miR-2
the CD117+CD44+CSCs were detected by qRT-PCR; C. The top and bottom
with the stable miR-200c overexpression under a fluorescence microscope
transduced with lentivirus-mock (left) or lentivirus miR-200c (right) in the st
the CD44+CD117+CSCs transduced with lentivirus-mock, the lentivirus miR-
E. E-cadherin was detected by IHC assay in tumors of mice injected with th
CD44+CD117+ CSCs, the CD44+CD117+ CSCs transduced with lentivirus-mo
in Figures 2, 3, 4 below.Plus glass slides, fixed in methanol, and stained in
hematoxylin and eosin (HE) [29,30].
Statistical analysis
Statistical comparisons of the results between groups were
performed using the Student’s t-test method. P < 0.05 was
considered significant statistically.
Results
Phenotype identification, morphologic characteristics
and miR-200c expression in lentivirus transduced
CD44+CD117+CSCs
As was described in the method section, the CD44+
CD117+CSCs were isolated from the SKOV-3 cell line
using MACS and were identified for cell phenotype using
FCM to study the miR-200c overexpression in CD44+
CD117+CSCs. Figure 1A shows that the CD44 and CD117
double-positive cells accounted for 3.1% of the SKOV-3
cell line, and were labeled ‘CD44+CD117+CSCs’ as was
done before [15]. Next, we detected the miR-200cssion in the CD44+ CD117+CSCs. A. The CD117+CD44+CSCs isolated
00c expression differences between the non CD117+CD44+CSCs and
panels show the morphological structures of the CD44+CD117+CSCs
and a light microscope, respectively. The CD44+CD117+CSCs
em cell culture medium; D. miR-200c expression differences among
200c and without lentivirus infection were detected by qRT-PCR.
e different cells. The labels ‘WT, mock and miR-200c’ denote the
ck, and the lentivirus miR-200c, respectively. These labels are also used
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miR-200c transduced CD44+CD117+CSCs after the cells
were stably selected using a single clone screening
method. Figure 1B indicates that the miR-200c expression
analyzed by qRT-PCR was markedly lower in the CD44+
CD117+CSCs than in the non CD44+CD117+CSCs. The
difference was statistically significant (p < 0.01). Morpho-
logically, the CD44+CD117+CSCs transduced with the
lentivirus miR-200c appeared to be fusiform-shaped and
closely connected clones in the media, whereas the CD44+
CD117+CSCs transduced with the lentivirus mock seemed
to have a looser and more dispersed structure (Figure 1C).
Figure 1D presents the results of the miR-200c expression
analyzed by qRT-PCR. The CD44+CD117+CSCs trans-
duced with the lentivirus miR-200c (the rightmost bar)
exhibited a significantly higher level of miR-200c
overexpression than the CD44+CD117+CSCs trans-
duced with the lentivirus mock (18 ± 5 vs 3 ± 1, P < 0.01)
or the CD44+CD117+CSCs (18 ± 5 vs 2 ± 1, P < 0.01).Figure 2 The CD44+CD117+CSCs transduced with lentivirus miR-200c
and cell proliferation in vitro. A. The plate colony forming assay; B. The w
the statistical analysis for the plate colony forming, the wound healing and
the different cells in vitro was detected by MTT assay. *p < 0.05 and ** p < 0Figure 1E presents the E-cadherin expression (brown
cells) stained with immunohistochemistry. The results
show that more brown cells were found in miR-200c-
CD44+CD117+CSCs of tumor tissue than the control
cells.
Effect of miR-200c overexpression on the capability of
colony formation and cellular motility of
CD44+ CD117+ CSCs
To characterize the function of miR-200c in the CD44+
CD117+CSCs, we examined the effects of miR-200c
overexpression on the CD44+CD117+CSCs with regard
to colony forming, cell migration, cell invasive ability,
and cell proliferation ability, respectively. The colony
forming capability was analyzed by the plate colony
forming assay. The plating colony formation rates were
about 60% and 50% for the CD44+CD117+CSCs and the
CD44+CD117+CSCs transduced with lentivirus mock,
respectively; the colony formation rates were less thanreduced the ability of colony forming, cell migration, invasion
ound healing assay; C. The transwell invasive assay; D-F. The results of
the transwell invasion, respectively. G: The cell proliferation ability of
.01.
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lentivirus miR-200c (Figure 2A, 2D). The cell migration
ability was assessed with the wound healing assay; the
results are displayed in the pictures in Figure 2B. The
overexpression of miR-200c clearly resulted in a signifi-
cant reduction in cell migration in comparison the con-
trol cells (CD44+CD117+CSCs with lentivirus mock and
CD44+CD117+CSCs without lentivirus infection); the
differences were statistically significant (Figure 2E). The
cell invasive ability was studied using the transwell inva-
sive assay. The overexpression of miR-200c resulted in
fewer CD44+CD117+CSCs with lentivirus miR-200c
(mean ± SD: 70.81% ± 2.16%), in the bottom of the
chamber insert, than in the CD44+CD117+CSCs with
lentivirus miR-200c compared with the CD44+CD117+
CSCs with lentivirus mock (125.92% ± 2.14%), or than
the CD44+CD117+CSCs without lentivirus infection
(162.26% ± 6.78%) (Figure 2C, 2F). The differences were
statistically significant. Figure 2G shows that the prolif-
eration ability of CD44+CD117+CSCs with lentivirus
miR-200c detected by MTT assay was slower than the
control cells.
Overexpression of miR-200c reduced ovarian tumor
formation and tumor burden
Because the miR-200c overexpression exhibited signifi-
cant effects on the colony forming and on the migratory
and invasion of CD44+CD117+CSCs in vitro, we sought
to determine whether the miR-200c overexpressionFigure 3 The miR-200c overexpression decreased tumor progression
CSCs transduced with lentivirus miR-200c or lentivirus-mock or without infe
The figure shows the tumor growth dynamic state in the mice injected wit
dissected from the mice on day 56 after injection. C. Tumor-free mice on dcould affect the establishment and progression of ovar-
ian cancer in vivo nude mouse model. Figure 3A shows
that the growth curves of the tumors in the mice
injected with the aforementioned CSCs. The images of
the tumors in Figure 3B were taken from the mice
injected with the different CSCs when the tumor tissues
were dissected on Day 56. Figure 3C indicates the sur-
vival time of the tumor-bearing mice. The mice injected
with the 5 × 104 CD44+CD117+CSCs with lentivirus
miR-200c showed much higher tumor free rates than
the mice injected with the 5 × 104 CD44+CD117+CSCs
with lentivirus mock or 5 × 104 CD44+CD117+CSCs with-
out lentivirus infection on different days after the injec-
tion. The differences were statistically significant (p < 0.01
in both comparisons). The results suggested that the stable
miR-200c overexpression in established tumors delayed
tumor progression.
miR-200c inhibited ZEB1,Vimentin and enhanced E-
Cadherin expression levels in tumor as well as decreased
tumor lung metastasis in nude mouse model
It is known that the feedback loop model links ZEB1 to
miR-200c in melanoma and breast cancer cells, and that
ZEB1 and miR-200c repress each other in the loop that
impacts the change in EMT-MET[10,23]. Therefore, we
wanted to find out whether the miR-200c overexpression
would also impact the ZEB1 expression in the tumors of
the nude mice that were injected with the CD44+
CD117+CSCs with lentivirus miR-200c. The resultsof CD44+ CD117+ CSCs in xenograft mice. A. 5 × 104 CD44+CD117+
ction were subcutaneously injected in the nude mice ( n = 6/group).
h the different CSCs (line, mean ± SE). B. Images of the tumor tissues
ay 56 after injection(line, mean ± SE). *p < 0.01 and ** p < 0.01.
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led to a marked reduction of ZEB1 mRNA (Figure 4A),
Vimentin mRNA (Figure 4B) and the protein expressions
(Figure 4D) compared with the CD44+CD117+CSCs with
lentivirus mock and with the CD44+CD117+CSCs without
lentivirus infection. Figures of 4E to 4G present the
quantities of the molecular expression from the grad-
ation scanning analysis. The miR-200c overexpression
in the tumors significantly increased the E-cadherin ex-
pression (Figure 4C, 4F). Because the stable miR-200c
overexpression in the established tumors delayed tumor
progression and extended the survival of the tumor-
bearing mice, we wanted to find out if the miR-200c
overexpression would inhibit tumor metastasis. Figure 4H
shows that the tumor lung metastasis was significantly re-
duced in the mice injected with the CD44+CD117+CSCsFigure 4 Impacts of the overexpression of miR-200c on ZEB1, E-Cadh
metastasis in mouse lungs. A-C. The qRT-PCR analysis results of the mRN
EOC-bearing nude mice after injection with CD44+CD117+CSCs. D. The pro
blotting analysis. E-G. The protein expression results from the gradation sca
hematoxylin and eosin). I. The statistically significant differences are indicatwith lentivirus miR-200c in comparison with the mice of
the two control groups (Figure 4I).
Effects of down-regulation of ZEB1 on colony formation,
migration, invasion of CD44+CD117+CSCs in vitro,
tumorigenicity, and tumor metastasis in vivo
Figure 5A displays the results from our experiment
that investigated the effects of the down-regulated
ZEB1 expression on the CD44+CD117+CSCs. The shZEB1
CD44+CD117+CSCs significantly decreased the colony
forming rates compared with the CD44+CD117+CSCs and
the scrambled CD44+CD117+CSCs, respectively; Figure 5D
indicates that the differences were statistically significant
(P < 0.01). Further, we evaluated the cell migration ability
in the shZEB1 CD44+CD117+CSCs. Figure 5B gives the
representative images of the cell migration in the flat plate.erin, and the Vimentin expressions in tumors, and tumor cell
A expression of ZEB1, Vimentin and E-Cadherin in the tumor tissues of
tein expression of ZEB1, E-Cadherin and Vimentin from the Western
nning analysis. H. The tumor metastasis in mouse lungs (stained in
ed by asterisk for **p < 0.01.
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cell migration due to the scratchy ‘wounds’ at the cell
edges. The results from the quantitative analysis at 48h
showed a statistically significant reduction in the wound
closures in the shZEB1 CD44+CD117+CSCs compared
with the CD44+CD117+CSCs and the scrambled CD44
+CD117+CSCs, respectively. Figure 5C illustrates the cell
invasive ability of the shZEB1 CD44+CD117+CSCs as was
measured by the transwell invasive assay; the differences
between the shZEB1 CD44+CD117+CSCs group and
the other two groups were both statistically significant
(P < 0.05 and P < 0.01 as shown in Figure 5F).
In light of the observed effects of the decreased
ZEB1 expression on colony forming, cell migration and
invasion in the shZEB1 CD44+CD117+CSCs in vitro,Figure 5 Down-regulation of ZEB1 inhibited the colony forming, cell
the results of the plate clone forming assay, the wound healing assay, and
statistical differences in the plate colony forming ratio, in the healing degre
shZEB1’ denote the CD44+CD117+CSCs, the CD44+CD117+CSCs stably trans
transfected with shZEB1, respectively. *p < 0.05 and **p < 0.01. These labelswe further validated whether the effects would impact
the tumorigenicity and metastatic potential of the
shZEB1 CD44+CD117+CSCs in vivo. Figure 6A shows
that all the 6 mice in this group developed tumors in
20 days after the injection of the 5 × 104 CD44+CD117+
CSCs; 5 of the 6 mice in the group receiving the
1 × 106 scrambled cells developed tumors in 26 days
after the injection. In contrast, only 3 of the 6 mice
injected with the 5 × 104 shZEB1 CD44+ CD117+CSCs
developed tumor on Day 22, Day 26 and Day 28, re-
spectively; the other 3 mice did not grow tumors
throughout the 56-day observation period (Figure 6B).
Figure 6C displays the photos of the tumor sizes and
quantity in the mice when the resultant xenograft
tumors were harvested.migration and invasion in vitro. A-C. The representative images from
the transwell invasive assay, respectively; D-F give the between-group
e, and in the invasive cells, respectively. The labels ‘WT, scramble and
fected with scramble shRNA, and the CD44+CD117+CSCs stably
are also used in Figure 6 below.
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of ZEB1, we examined the expression of ZEB1, E-
cadherin and Vimentin, respectively, in the tumor tis-
sues of the EOC-bearing nude mice. The Western blot
results indicated that the expression of ZEB1 and
Vimentin was much lower, and the E-Cadherin expres-
sion was much higher in the mice injected with the
shZEB1 CD44+CD117+CSCs than in the mice injected
with the CD44+CD117+CSCs or with the scrambled
CD44+CD117+CSCs (Figure 6D). Figures 6E to 5G
show the quantities of the molecular expression from
the gradation scanning analysis.
To assess the effect of the down-regulation of ZEB1
on tumor metastasis, we performed H&E staining of
lung tissue sections. Compared with the mice of the two
control groups, a few tumor metastasis were found in
the lungs of the nude mice injected with the shZEB1
CD44+CD117+CSCs (Figure 6H and 6I). It is thusFigure 6 Down-regulation of ZEB1 reduced tumor growth and metas
curves and tumor bearing mice’ survival. C. The photos of the tumor tissue
expression results from the Western blotting analysis. E-G. The protein expr
results from the tumor tissue sections at 400× magnification; The tumor ce
and the CD44+CD117+ scramble (+++); a few tumor cells were seen in the
The statistical analysis results of the metastatic tumor cells in the lungs of tevident from the results that the EMT-phenotype tumor
cell growth and metastasis were significantly inhibited in
the mice injected with the shZEB1 CD44+CD117+CSCs
compared with the mice injected with the CD44+
CD117+CSCs or the scrambled CD44+CD117+CSCs.
Discussion
EOC CSCs that undergo the EMT have demonstrated
that the tumor cells are in general less differentiable,
more invasive, more chemoresistant, and result in poor
clinical outcomes [7]. Numerous studies of EOC have
focused on modulating the miR-200 family (including
miR-200a, miR-200b, miR-200c, and miR-141) [31-34].
However, it is unknown whether the EOC CSCs, the
“seed cells” in EOC, are closely associated with the miR-
200 family expression.
The findings from our study demonstrated that the
population of the rare CD44+CD117+CSCs (3.1%) existedtasis in vivo xenograft mouse. A-B. The tumor dynamic growth
s dissected from the mice on day 56 after injection. D. The protein
ession results from gradation scanning analysis. H. The HE staining
ll metastases were visible in the samples of the CD44+CD117+WT(+++)
lungs of the nude mice injected with the CD44+CD117+shZEB1 (+). I.
he mice injected with the different CSCs. *p < 0.05 and **p < 0.01.
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http://www.ovarianresearch.com/content/6/1/50in the human EOC SKOV3 cell line, and that the CD44+
CD117+CSCs showed lower expression of miR-200c than
the non CD44+CD117+CSCs. With the stable miR-200c
overexpression in the CD44+CD117+CSCs, the cells mark-
edly decreased the colony forming capability. It is known
that the tumor cell cloning efficiency is correlated posi-
tively with the cellular proliferation and self-renewal abil-
ity that may be associated with the cell tumorigenesis
[23,24]. The results from our colony forming assay indi-
cated that the small subset of the CD44+CD117+CSCs had
a strong colony forming capability, which signified that
the CD44+CD117+CSCs might have powerful tumorigen-
esis in the mouse model. In our tumorigenesis analysis, we
found that all 6 nude mice injected with the 5 × 104 CD44
+CD117+CSCs developed tumors in 21 days after the in-
jection. In comparison, for the group that was injected
with the 5 × 104 CD44+ CD117+CSCs with the miR-200c
overexpression, only 3 out of the 6 mice with equal injec-
tion of 5 × 104 cells developed tumors after 56 days into
the observation; the tumor sizes of these 3 mice were also
smaller than those of the control group mice. These re-
sults suggested that the miR-200c overexpression not only
effectively decreased the colony forming capability but
also obviously reduced the tumorigenicity and the tumor
burden in our establishment mouse model.
In EOC, metastases account for the majority of deaths
from gynecologic malignancies [35,36], therefore,
we next explored the relationship between the miR-
200c overexpression and tumor metastases. The
cell migration and invasion in vitro results indica-
ted that the stable miR-200c overexpression in the
CD44+CD117+CSCs reduced cell migration and inva-
sion. It is well known that the cell migration and inva-
sion in vitro are definitely associated with of cell
metastases in vivo; this was confirmed by the lung me-
tastasis in the mice in our study. The lung tumor metas-
tasis in the mice injected with the CD44+CD117+CSCs
with lentivirus miR-200c was markedly decreased. To
study the efficacy of decreased tumor metastasis in the
lungs of the mice in the study, we wanted to understand
what molecular mechanism of reduced the tumor metas-
tasis; we investigated this by detecting the characteristic
biomarkers of E-cadherin (epithelial cells),Vimentin (mes-
enchymal cells), and ZEB1 (in association with EMT) in
tumor tissues [9,37]. We noticed that the enforced
overexpression of miR200c in the CD44+CD117+CSCs sig-
nificantly reduced the expressions of both ZEB1 and
Vimentin, but increased the expression of E-cadherin
in the RNA and the protein levels in tumor samples. Ap-
parently, the miR-200c overexpression decreased the
ZEB1 expression, which directly inhibited the EMT of the
CD44+CD117+CSCs, and reduced the CSC metastasis po-
tential. Our findings were in agreement with a recent re-
port that the overexpression of miR-429, a member of themiR-200 family of microRNAs, in the mesenchymal-like
ovarian cancer cells resulted in the mesenchymal–epithe-
lial transition [33].
To assess the relationship between ZEB1 and miR-200c
in the CD44+CD117+CSCs, we asked whether the down-
regulation of ZEB1 would have similar effects as the miR-
200c overexpression. We found that the down-regulation
of the ZEB1 expression in the CD44+CD117+CSCs indeed
had the similar effects as the miR-200c overexpression in
the CD44+CD117+CSCs; this was reflected in the signifi-
cant suppression of the tumorigenesis and tumor metasta-
sis in the mice injected with the shZEB1 CD44+CD117+
CSCs in comparison with the mice injected with the
CD44+CD117+CSCs or with the CD44+CD117+CSCs with
lentivirus mock. It is therefore reasonable to conclude that
ZEB1 was essential for tumorigenesis and metastasis in xe-
nografts transplantation experiments, and that the down-
regulation of ZEB1 may not only be a useful biomarker of
the EMT in the EOC CSCs, but also serve as a potential
therapeutic target to inhibit EOC metastasis [33,37].
In summary, the findings from our experiments demon-
strate that the overexpression of miR-200c significantly re-
duced the CD117+CD44+CSCs xenograft growth and lung
metastasis in vivo, partially through the reversal of the
EMT phenotype. The down- regulation of the ZEB-1 ex-
pression in the CD117+CD44+CSCs induced the similar
effects as the miR-200c overexpression. These findings
may enable us to design a feasible strategy for the modula-
tion of EMT in the CD44+CD117+CSCs for clinical EOC
treatment.
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